NG-2001

NG-2001 is a preclinical mRNA-based immunotherapy candidate developed by NanoGhost for the treatment of solid tumors. It utilizes the proprietary NanoGhost delivery platform, which consists of nanovesicles derived from mesenchymal stem cell (MSC) membranes. These vesicles leverage the natural tropism of MSCs to selectively target and penetrate tumor cells, acting as a 'Trojan horse' for the therapeutic payload. Once inside the tumor microenvironment, NG-2001 delivers mRNA designed for immune-oncology applications, though the specific encoded antigen or immunomodulatory mechanism has not been publicly disclosed. The therapy aims to provide a targeted, non-toxic delivery system for mRNA cancer treatments, with clinical trials anticipated to begin around 2027.